By Jimmy Downs

Wednesday May 22, 2013 (foodconsumer.org) -- Researchers at Cancer Treatment Centers of America (CTCA) have recently conducted a phase I clinical trial and found high dose vitamin C through IV administration could potentially be used to treat cancer.

The results of the trial published in the May edition of Cancer Chemotherapy and Pharmacology show that IV administration of vitamin C in a dose of 56 grams /M2, which resulted in a blood concentration of vitamin C at 26 mM, inhibited tumor growth in mice.

While serum vitamin C at 30 to 40 mM only partially inhibited the growth of tumor growth and did not cause tumor regression, Robert Levin , MD, and Christopher M. Stephenson , DO, investigators of the trial report that the serum ascorbic acid (vitamin C) could be reached at 49 mM by IV administration of vitamin C in a dose of 70 to 80 grams/m2 and in this dose, vitamin C appeared to have a potential for an anti-cancer actvity in future trials.

IV-injection of vitamin C has been used by some alternative clinics worldwide to treat cancer. Dr. Linus Pauling advocated taking a high dose of vitamin C to prevent a variety of diseases including cancer.  But the mainstream medical circle does not recognize that vitamin C can be used as a first line medicine to treat any major disease.

The investigators also conducted other research showing that vitamin C can be used to potentiate the antitumor activity of chemotherapy like gemcitabine against seven human and one murine pancreatic cancer in vitro.  This is important because two lines of cancer cells were resistant to gemcitabine.

Also vitamin C was found to have a synergistic antitumor activity with chemotherapy in tissue culture and in vivo studies with implanted tumors in mice.

In a press release, Cancer Treatment Centers of America reported that at pharmacologic levels vitamin C decreased tumor volumes in eight out of nine patients.